Patient Death Does Not Augur Doom, But Kite Pharma Needs To Shut Its Big Mouth.

KITE Pharma Inc.; CLINICAL trials; HEMATOLOGIC malignancies; CANCER patients; CANCER treatment; CELLULAR therapy

The article reports on a patient who died in a trial of cell therapy for a form of blood cancer being conducted by Kite Pharma. Topics discussed include chimeric antigen receptor t-cells (CAR-T), the announcement made by Kite Pharma chief executive Arie Belldegrun in a conference, and the analysis of Tony Butler of Guggenheim Partners. Kite Pharma rivals Juno Therapeutics and Novartis are mentioned.